GlassScriptPhysician profile
Sanjay Y Sheth
NPI 1285616383
$16,171.85
in general payments reported to CMS, 2019-2025
41 companies · $2,656 in 2025
The $2,656 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,988 · 2020: $1,224 · 2021: $2,306 · 2022: $2,605 · 2023: $2,603 · 2024: $2,789 · 2025: $2,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,048.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,559.82 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,161.67 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,010.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $976.68 | 2019-2025 | |
| Novo Nordisk INC | $918.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $904.99 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $889.72 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $853.92 | 2020-2025 | Repatha, Krystexxa, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $844.74 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $646.99 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $517.88 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $485.74 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $449.03 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $421.34 | 2019-2024 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $326.03 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.